Holen Sie sich die Stockscreener-App
8.0965
3.60%
0.3165
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$7.78
Offen:
$7.8
24-Stunden-Volumen:
7.12M
Relative Volume:
0.96
Marktkapitalisierung:
$1.51B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.86M
KGV:
-32.94
EPS:
-0.2458
Netto-Cashflow:
$-28.39M
1W Leistung:
+6.19%
1M Leistung:
+80.72%
6M Leistung:
+452.05%
1J Leistung:
+326.46%
1-Tages-Spanne:
$7.41
$8.36
1-Wochen-Bereich:
$6.9602
$9.0999
52-Wochen-Spanne:
$1.39
$9.0999
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Firmenname
Sellas Life Sciences Group Inc
Sektor
Branche
Telefon
(646) 200-5278
Adresse
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
8.102 | 1.45B | 0 | -26.86M | -28.39M | -0.2458 |
VRTX
Vertex Pharmaceuticals Inc
|
437.16 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.85 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.07 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.23 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.03 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-01 | Eingeleitet | Oppenheimer | Outperform |
| 2018-04-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Hochstufung | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten
SLS Stock Heads For Their Best Month This Year Ahead Of Key AML Trial Readout - Yahoo Finance
What’s Fueling SLS Stock? Delayed AML Trial Readout, A Knicks Analogy, And A 185% Rally This Year - Stocktwits
SLS Stock Rallies After Hours As CEO Teases Leukemia Study Data Any Day Now - Stocktwits
SLS stock hits 4-year high: BlackRock stake boost fuels buzz around looming AML trial readout - MSN
SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, ‘Whole Gamut’ Of Cancer Uses For GPS - Stocktwits
SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst - Stocktwits
Why did ARM, SLS, EBAY stocks surge to 52-week highs? - MSN
SLS stock tanks hard: Retail traders blame warrant holders, 'flippers' cashing out before AML catalyst - MSN
SLS stock pops big after hours on imminent leukemia trial data readout optimism - MSN
SLS stock rallies after hours as CEO teases leukemia study data any day now - MSN
NBIS, CSCO, SLS stocks hit 52-week highs today: What's behind the surge? - MSN
SLS stock hits over 4-year high: CEO eyes FDA talks, ‘whole gamut’ of cancer uses for GPS - MSN
Sellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish Signal (NASDAQ:SLS) - Seeking Alpha
Assessing SELLAS Life Sciences Group (SLS) Valuation After Strong Multi-Year Returns And A Sharp One-Day Share Price Drop - simplywall.st
SLS stock jumps premarket: CEO says GPS AML data has ‘very good chance’ to beat earlier survival outcomes - MSN
SELLAS Life Sciences Group Down Nearly 19%, on Pace for Largest Percent Decrease Since March 2024 -- Data Talk - Moomoo
SLS Stock Pulls Back As Cash Pile Extends Biotech Runway - StocksToTrade
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
Why Did ARM, SLS, EBAY Stocks Surge To 52-Week Highs? - Stocktwits
SLS: Pivotal data for GPS and SLS-009 in AML expected by year-end, backed by strong financials - TradingView
SLS Stock Jumps As Cash Pile Grows And Trial Catalysts Near - StocksToTrade
SLS Stock Jumps As SELLAS Boosts Cash And Near-Term Catalysts - timothysykes.com
SELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move? - Benzinga
SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus - TechStock²
SLS: Imminent phase III and II data for GPS and SLS009 in AML signal major near-term catalysts - TradingView
SLS: GPS and SLS-009 advance in AML, with pivotal data and biomarker-driven expansion expected soon - TradingView
SLS Technical Analysis | Trend, Signals & Chart Patterns | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SLS stock heads for weekly win: Deutsche Bank’s stake boost draws attention ahead of Q1 earnings - MSN
SLS Stock Price, Quote & Chart | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SELLAS Life Sciences (SLS) Nears Pivotal AML Data as Cash, Pipeline and ATM Plan Reframe Its Story - simplywall.st
SLS on track to clock best week in over 4 months: Retail divided between stock drop or multibagger status amid upcoming leukemia trial readout - MSN
SELLAS Life Sciences Group (SLS) price target increased by 15.38% to 10.20 - MSN
SELLAS Life Sciences Group, Inc.Common Stock (NQ: SLS - FinancialContent
SLS Stock Surges Into Conference Season As Investors Hunt For AML Readout Hints - Stocktwits
Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade - MSN
SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism - Stocktwits
SLS Stock Hits 4-Year High: BlackRock Stake Boost Fuels Buzz Around Looming AML Trial Readout - Stocktwits
SLS stock surges into conference season as investors hunt for AML readout hints - MSN
Finanzdaten der Sellas Life Sciences Group Inc-Aktie (SLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sellas Life Sciences Group Inc-Aktie (SLS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| VAN NOSTRAND ROBERT L | Director |
Jun 12 '25 |
Buy |
1.48 |
10,000 |
14,800 |
20,400 |
| Wasman Jane | Director |
May 30 '25 |
Buy |
1.69 |
20,000 |
33,800 |
30,400 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):